GT Biopharma price target lowered to $3 from $8 at Roth Capital

Roth Capital analyst Jonathan Aschoff lowered the firm’s price target on GT Biopharma (GTBP) to $3 from $8 and keeps a Buy rating on the shares. The firm is citing the company evaluating second-generation TriKE GTB-3650 in a Phase 1 trial in rel/ref CD33 expressing hematologic malignancies, predominantly AML and high-risk MDS, with initial data expected in 3Q26 following completion of cohort 5, the analyst tells investors in a research note.